242 related articles for article (PubMed ID: 22452635)
41. Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes.
Hussein AA; Welty CJ; Ameli N; Cowan JE; Leapman M; Porten SP; Shinohara K; Carroll PR
J Urol; 2015 Jul; 194(1):85-90. PubMed ID: 25623742
[TBL] [Abstract][Full Text] [Related]
42. CD105 expression is an independent predictor of survival in patients with endometrial cancer.
Erdem O; Taskiran C; Onan MA; Erdem M; Guner H; Ataoglu O
Gynecol Oncol; 2006 Dec; 103(3):1007-11. PubMed ID: 16854456
[TBL] [Abstract][Full Text] [Related]
43. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer.
Gravdal K; Halvorsen OJ; Haukaas SA; Akslen LA
Cancer Res; 2009 Jun; 69(11):4708-15. PubMed ID: 19487287
[TBL] [Abstract][Full Text] [Related]
44. Reconsideration of the clinical and histopathological significance of angiogenesis in prostate cancer: Usefulness and limitations of microvessel density measurement.
Miyata Y; Sakai H
Int J Urol; 2015 Sep; 22(9):806-15. PubMed ID: 26153072
[TBL] [Abstract][Full Text] [Related]
45. STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score.
Gomes IM; Arinto P; Lopes C; Santos CR; Maia CJ
Urol Oncol; 2014 Jan; 32(1):53.e23-9. PubMed ID: 24239460
[TBL] [Abstract][Full Text] [Related]
46. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
[TBL] [Abstract][Full Text] [Related]
47. Transforming growth factor-beta binding receptor endoglin (CD105) expression in esophageal cancer and in adjacent nontumorous esophagus as prognostic predictor of recurrence.
Bellone G; Solerio D; Chiusa L; Brondino G; Carbone A; Prati A; Scirelli T; Camandona M; Palestro G; Dei Poli M
Ann Surg Oncol; 2007 Nov; 14(11):3232-42. PubMed ID: 17682823
[TBL] [Abstract][Full Text] [Related]
48. COX-2 is overexpressed in primary prostate cancer with metastatic potential and may predict survival. A comparison study between COX-2, TGF-beta, IL-10 and Ki67.
Richardsen E; Uglehus RD; Due J; Busch C; Busund LT
Cancer Epidemiol; 2010 Jun; 34(3):316-22. PubMed ID: 20409773
[TBL] [Abstract][Full Text] [Related]
49. Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers.
Stumm L; Burkhardt L; Steurer S; Simon R; Adam M; Becker A; Sauter G; Minner S; Schlomm T; Sirma H; Michl U
J Clin Pathol; 2013 Jul; 66(7):563-8. PubMed ID: 23559350
[TBL] [Abstract][Full Text] [Related]
50. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
51. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
Khatami A; Hugosson J; Wang W; Damber JE
Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
[TBL] [Abstract][Full Text] [Related]
52. Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival.
Lissbrant IF; Stattin P; Wikstrom P; Damber JE; Egevad L; Bergh A
Int J Oncol; 2000 Sep; 17(3):445-51. PubMed ID: 10938382
[TBL] [Abstract][Full Text] [Related]
53. Active surveillance for low-risk prostate cancer: Need for intervention and survival at 10 years.
Preston MA; Feldman AS; Coen JJ; McDougal WS; Smith MR; Paly JJ; Carrasquillo R; Wu CL; Dahl DM; Barrisford GW; Blute ML; Zietman AI
Urol Oncol; 2015 Sep; 33(9):383.e9-16. PubMed ID: 26059076
[TBL] [Abstract][Full Text] [Related]
54. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
[TBL] [Abstract][Full Text] [Related]
55. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment.
García-Cruz E; Piqueras M; Huguet J; Peri L; Izquierdo L; Musquera M; Franco A; Alvarez-Vijande R; Ribal MJ; Alcaraz A
BJU Int; 2012 Dec; 110(11 Pt B):E541-6. PubMed ID: 22584031
[TBL] [Abstract][Full Text] [Related]
56. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
Loeb S; Berglund A; Stattin P
J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
[TBL] [Abstract][Full Text] [Related]
57. Endoglin (CD105) expression in human renal cell carcinoma.
Sandlund J; Hedberg Y; Bergh A; Grankvist K; Ljungberg B; Rasmuson T
BJU Int; 2006 Apr; 97(4):706-10. PubMed ID: 16536758
[TBL] [Abstract][Full Text] [Related]
58. Endoglin (CD 105) as a potential prognostic factor in neuroblastoma.
Ćavar S; Jelašić D; Seiwerth S; Milošević M; Hutinec Z; Mišić M
Pediatr Blood Cancer; 2015 May; 62(5):770-5. PubMed ID: 25683142
[TBL] [Abstract][Full Text] [Related]
59. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy.
Bubendorf L; Sauter G; Moch H; Schmid HP; Gasser TC; Jordan P; Mihatsch MJ
J Pathol; 1996 Apr; 178(4):437-41. PubMed ID: 8691323
[TBL] [Abstract][Full Text] [Related]
60. Independent prognostic importance of microvessel density in clinically localized prostate cancer.
Halvorsen OJ; Haukaas S; Høisaeter PA; Akslen LA
Anticancer Res; 2000; 20(5C):3791-9. PubMed ID: 11268456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
